Nomura

New Business

Can rising lithium costs save China’s energy storage firms from a brutal price war?

China’s energy storage firms, battered by a three-year price war, have been jolted by lithium battery maker Deegares, which has…

Read More »
New Business

As homes fail to sell in mainland China’s depressed market, sellers turn to superstition

For homeowners in mainland China, selling a property has become so difficult that some are turning to xuanxue, a neo-Taoist…

Read More »
New Business

China’s stock boom will not do much to rejuvenate the economy, Nomura says

The ongoing rally in Chinese stocks will do little to boost growth in the mainland’s economy, as equity investments account…

Read More »
New Business

Can China pass on-the-ground tests to ace its economic report card in 2025’s second half?

Having gone five years without a raise, and now facing increased odds of being laid off, a 36-year-old accountant in…

Read More »
New Business

Developing | China’s economy withstands US tariff war with 5.2% growth in second quarter

China’s economy expanded by 5.2 per cent in the second quarter, keeping it broadly on track to meet this year’s…

Read More »
New Business

South Korea, Japan step up as US targets China’s shipbuilding industry – can they succeed?

As the United States vows to curb China’s dominance in shipbuilding – despite its domestic capacity being nearly nonexistent –…

Read More »
New Business

Why 1 clause in the US-Vietnam trade deal is sparking concern across Asia

The United States announced it had reached a trade deal with Vietnam on Wednesday, which will see Washington impose a…

Read More »
New Business

Is China’s massive trade-in programme running out of steam?

For months, consumers across China buying everything from iPhones to cars and washing machines have enjoyed steep discounts – courtesy…

Read More »
New Business

The View | Why South Korean real estate is a good barometer for Asia

South Korea has been in the spotlight of late. Earlier this month, Lee Jae-myung, the candidate of the left-leaning Democratic…

Read More »
New Business

Chinese biotech firm Akeso tumbles on US partner Summit’s setback for cancer drug

Chinese biotech firm Akeso, whose cancer drug has been hailed as a breakthrough for the nation’s pharmaceutical industry, suffered a…

Read More »
Back to top button